Type 2 Diabetes
Conditions
Brief summary
Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2 diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.
Detailed description
Glycemic fluctuation is a major problem in glucose control in diabetic patients. It is interesting to know that whether weekly GLP-1RA can improve glycemic variability in diabetic patients. The present study aims to assess the effect of dulaglutide on glycemic variability using continuous glucose monitor(CGM) (Libra, Abbott) in type 2 diabetic patients with 4 weeks.
Interventions
Dulaglutide 1.5Mg qw sc injection for 4 weeks
Sponsors
Shanghai Zhongshan Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Fully understand the test content and possible adverse reactions and voluntarily participate in the trial and sign the informed consent form; * Meet the World Health Organization(WHO) (1999) criteria for the diagnosis and classification criteria for type 2 diabetes; * 18 ≤ age ≤ 70 years old, male or female;
Exclusion criteria
* Subjects with Type 1 diabetes mellitus or secondary diabetes mellitus (i.e. any type other than T2DM) * Personal history or family history of thyroid medullary carcinoma or multiple endocrine neoplasia type 2 (MEN2). * History of pancreatitis or considered clinically at significant risk of developing pancreatitis during the course of the study (e.g. due to symptomatic gallstones). * History of significant gastrointestinal (GI) surgery that in the opinion of the investigator is likely to significantly affect upper GI or pancreatic function. * Fasting triglyceride level more than 750 mg/dL at screening. * Estimated Glomerular Filtration Rate (eGFR) less than 60 mL/minute/1.73 meter\^2 (calculated using the Schwartz equation) at screening. * ALT more than 2.5x upper limit of normal (ULN) or Bilirubin more than 1.5xULN (isolated bilirubin more than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin more than 35%) at screening. * Use of a GLP-1receptor agonist at study entry and during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect on glycemic variability | one months | The FreeStyle Libre Pro (Abbott Co., Ltd) will be used to monitor glucose levels during the four weeks from the day before the first administration of the study drug |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effect on Glycemic Control | one months | It will be assessed at baseline and after one months of treatment to determine the anti-diabetic effect of dulaglutide |
Countries
China
Outcome results
None listed